查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1438216

2030 年布氏桿菌症疫苗市場預測：按疫苗類型、疾病、通路、應用、最終用戶和地區進行的全球分析

Brucellosis Vaccine Market Forecasts to 2030 - Global Analysis By Vaccine Type, Disease, Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球布氏桿菌症疫苗市場規模為 2.396 億美元，預測期內年複合成長率為 6.70%，到 2030 年將達到 3.774 億美元。

布氏桿菌症疫苗是針對布氏桿菌屬的預防措施，布魯氏菌病是一種影響動物和人類的通用感染疾病的病原體。此疫苗主要用於牛、山羊和綿羊等牲畜。疫苗有助於控制布氏桿菌屬感染的傳播，並降低接觸受污染的動物食品或直接接觸受感染的動物而傳播給人類的風險。

美國農業部 (USDA) 報告稱，美國約有 9,190 萬頭牛和牛。同樣，根據美國農業部的一份報告，印度的牛存欄量預計將增加，到 2022 年將達到 3.067 億頭。

布魯氏菌病流行

布魯氏菌病在全世界構成重大健康和經濟威脅，特別是在人類和動物密切接觸的地區，增加了對有效疫苗的需求。各國政府、牲畜所有者和衛生保健機構越來越認知到透過疫苗接種來控制布氏桿菌症傳播的重要性。這種認知的提高，加上對永續農業實踐的日益成長的需求，正在推動相關人員積極尋求和投資創新的疫苗解決方案，以減少這種感染疾病的影響，從而推動布氏桿菌症疫苗市場的擴張。

抗生素治療選擇

抗生素治療選擇作為布氏桿菌症疫苗市場的限制因素發揮關鍵作用。強力黴素和利福平等抗生素對於控制和治療人類感染疾病至關重要。對抗菌治療的依賴可能會阻礙布氏桿菌症疫苗市場的成長，因為有效的藥物可以提供快速作用並減少預防性疫苗接種的需求。此外，開發普遍有效的布氏桿菌症疫苗所面臨的挑戰進一步強調了抗菌療法對於解決疾病當前負擔的重要性。

不斷發展的畜牧業

隨著全球對肉類和乳製品的需求不斷增加，畜牧農民正在努力確保牛的健康和生產力。布魯氏菌病導致牛和羊的繁殖問題，導致畜牧業的經濟損失。有效的布氏桿菌症疫苗的開發和普及將提供預防性解決方案，減少疾病的流行，並促進牲畜的整體福祉。畜牧農民越來越重視疾病管理，以提高牲畜經營的永續性和盈利，為疫苗製造商創造了一個利潤豐厚的市場。

認知和教育有限

布氏桿菌症疫苗市場的認知和教育有限的威脅源於相關人員（包括醫療保健相關人員和公眾）的知識和理解不足。這種認知的缺乏可能會阻礙布氏桿菌症疫苗的採用並導致疫苗接種率低。對布氏桿菌症的嚴重性和疫苗接種益處的教育不足可能會導致低估該疾病的影響並阻礙控制其傳播的努力。應對這項威脅需要進行有針對性的教育宣傳活動，以提高醫療保健提供者、政策制定者和一般民眾的意識。

COVID-19 的影響：

由於資源和重點已轉移到應對全球健康危機上，布氏桿菌症疫苗的開發、生產和分銷已陷入停滯。研究和投資重點正在發生變化，影響布氏桿菌症疫苗的整體進展和可用性。此外，供應鏈中斷和後勤挑戰進一步阻礙了疫苗的取得。隨著對抗 COVID-19 的鬥爭繼續進行，布氏桿菌症疫苗市場面臨延誤和不確定性，可能會影響人類和動物群體中這種細菌感染的控制。

預計病毒性疾病領域在預測期內將是最大的

由於人們對這種細菌感染疾病的認知和努力的提高，病毒性疾病領域正在經歷顯著的成長。此外，針對布氏桿菌屬的創新研究和發展導致了投資和進展的激增。此外，這種成長是由製藥公司、研究機構和政府為解決布氏桿菌症引起的重大公共衛生問題而採取的合作方法所推動的。

動物照護中心產業預計在預測期內年複合成長率最高

由於人們認知的提高和控制動物布氏桿菌症傳播的積極措施，動物護理中心行業正在經歷顯著成長。隨著對動物健康和福利的日益重視，獸醫院和護理中心正在積極將布氏桿菌症疫苗接種計劃納入其服務中。這一激增也是由旨在減少布氏桿菌症對經濟和公共衛生影響的監管努力所推動的。此外，隨著牲畜和伴同性動物飼主尋求預防解決方案，動物照護中心對布氏桿菌症疫苗的需求正在增加。

佔比最高的地區

北美在全球市場中佔據主導地位，預計在預測期內將保持其地位。成長的潛在因素包括布氏桿菌症預防意識的提高、對牲畜健康管理的需求增加以及政府促進動物健康的措施。該地區先進的獸醫基礎設施和研究能力也促進了布氏桿菌症疫苗的開發和採用。畜牧業是該地區疫苗接種需求的主要動力。生物學研究鼓勵針對動物福利的疾病特異性疫苗的開發。

年複合成長率最高的地區：

預計亞太地區市場在預測期內將以顯著的成長率擴大。這一成長歸因於該地區（尤其是中國）肉類消費和貿易的持續成長。中國對肉類的需求不斷成長，使其成為養殖動物動物保健品的最大市場之一。對乳製品和肉類產品的需求不斷增加，加上畜牧業生產的激增，正在推動對有效疫苗的需求。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間存在敵對關係

第5章全球布氏桿菌症疫苗市場：依疫苗類型

  • DNA疫苗
  • 次單位疫苗
    • 結合疫苗
    • 重組疫苗
    • 類毒素疫苗
  • 無效
  • 活腐爛
  • mRNA疫苗
  • 載體疫苗
  • 病毒載體疫苗
  • 其他類型的疫苗

第6章全球布氏桿菌症疫苗市場：依疾病分類

  • 病毒性疾病
    • COVID-19
    • 肝炎
    • 帶狀皰疹
    • 人類乳突病毒
    • 麻疹、腮腺炎、德國麻疹
    • 流感
    • 輪狀病毒
    • 其他病毒性疾病
  • 細菌疫苗
    • 白喉 百日咳 破傷風
    • 肺炎球菌疾病
    • 腦膜炎球菌疾病
    • 其他細菌疫苗
  • 過敏疫苗
  • 癌症疫苗
  • 其他疾病

第7章全球布氏桿菌症疫苗市場：依通路分類

  • 醫院和零售藥房
  • 政府供應商
  • 其他分銷管道

第8章全球布氏桿菌症疫苗市場：依應用分類

  • 牛
  • 山羊
  • 馬
  • 羊
  • 豬
  • 其他用途

第9章全球布氏桿菌症疫苗市場：依最終用戶分類

  • 獸醫醫院和診所
  • 動物保護中心
  • 其他最終用戶

第10章全球布氏桿菌症疫苗市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第11章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司簡介

  • Biogenesis-Bago
  • Biovet
  • Boehringer Ingelheim
  • Calier
  • Ceva Sante Animale
  • Colorado Serum
  • CZ Veterinaria
  • Hester Biosciences
  • Indian Immunologicals
  • Onderstepoort Biological
  • Qilu
  • SYVA Laboratorios
  • Technovax
  • Zoetis
Product Code: SMRC25185

According to Stratistics MRC, the Global Brucellosis Vaccine Market is accounted for $239.6 million in 2023 and is expected to reach $377.4 million by 2030 growing at a CAGR of 6.70% during the forecast period. The Brucellosis vaccine is a preventive measure against Brucella bacteria, which cause brucellosis-a zoonotic disease affecting animals and humans. The vaccine is primarily administered to livestock such as cattle, goats, and sheep, as these animals are common reservoirs for the bacteria. The vaccine helps control the spread of brucella infections, reducing the risk of transmission to humans through contact with contaminated animal products or direct contact with infected animals.

According to the report of the United States Department of Agriculture (USDA), there were about 91.9 million cattle and calves in the United States. Similarly, report of the USDA, the population of cattle in India is expected to increase and reach 306.7 million in 2022.

Market Dynamics:

Driver:

Prevalence of brucellosis

With Brucellosis posing substantial health and economic threats globally, particularly in regions with close human-animal interaction, the demand for effective vaccines has risen. Governments, livestock owners, and healthcare authorities are increasingly recognizing the importance of prevention through vaccination to control the spread of Brucellosis. This heightened awareness, coupled with a growing need for sustainable agricultural practices, fuels the expansion of the brucellosis vaccine market as stakeholders actively seek and invest in innovative vaccine solutions to mitigate the impact of this infectious disease.

Restraint:

Antimicrobial treatment options

Antimicrobial treatment options play a crucial role in the restraint of the Brucellosis vaccine market. Antibiotics such as doxycycline and rifampin are essential for managing and treating the infection in humans. This reliance on antimicrobial therapies may hinder the growth of the Brucellosis vaccine market, as effective drugs can provide immediate relief and may reduce the perceived need for preventive vaccination. Additionally, challenges in developing a universally effective brucellosis vaccine further emphasize the significance of antimicrobial treatments in addressing the current burden of the disease.

Opportunity:

Growing livestock industry

As the demand for meat and dairy products rises globally, livestock farmers are keen on ensuring the health and productivity of their herds. Brucellosis can cause reproductive issues in cattle and sheep, leading to economic losses in the industry. The development and widespread adoption of effective Brucellosis vaccines offer a preventive solution, reducing the prevalence of the disease and promoting overall livestock well-being. This presents a lucrative market for vaccine manufacturers, as farmers increasingly prioritize disease management to enhance the sustainability and profitability of their livestock operations.

Threat:

Limited awareness and education

The limited awareness and education threat in the Brucellosis vaccine market arises from insufficient knowledge and understanding among stakeholders, including healthcare professionals and the public. This lack of awareness may hinder the adoption of brucellosis vaccines, leading to lower vaccination rates. Inadequate education about the severity of brucellosis and the benefits of vaccination can contribute to an underestimation of the disease's impact, potentially impeding efforts to control its spread. Addressing this threat requires targeted educational campaigns to enhance awareness among healthcare providers, policymakers, and the general population.

Covid-19 Impact:

The diversion of resources and focus towards combating the global health crisis has led to a slowdown in the development, production, and distribution of brucellosis vaccines. Research and investment priorities have shifted, affecting the overall progress and availability of vaccines for Brucellosis. Additionally, disruptions in supply chains and logistical challenges have further hindered vaccine accessibility. As efforts continue to address COVID-19, the Brucellosis vaccine market faces delays and uncertainties, potentially affecting the control of this bacterial infection in both human and animal populations.

The viral diseases segment is expected to be the largest during the forecast period

The viral diseases segment is experiencing notable growth due to increasing awareness and efforts to combat this bacterial infection. And encompassing innovative research and development targeting Brucella strains, has witnessed a surge in investment and advancements. Furthermore, this growth is driven by a collaborative approach between pharmaceutical companies, research institutions, and governmental initiatives to address the significant public health concern posed by brucellosis.

The animal care centers segment is expected to have the highest CAGR during the forecast period

The Animal Care Centers segment is experiencing notable growth due to increasing awareness and proactive measures taken to control the spread of brucellosis in animals. With a rising emphasis on animal health and welfare, veterinary clinics and care centers are actively incorporating brucellosis vaccination programs into their services. This surge is also driven by regulatory efforts to mitigate the economic and public health impacts of brucellosis. Additionally, as livestock and companion animal owners seek preventive solutions, the demand for brucellosis vaccines within animal care centers is expanding.

Region with largest share:

North America dominated the global market and is expected to retain its position during the forecast period. Potential factors contributing to growth includes increased awareness about brucellosis prevention, rising demand for livestock health management, and government initiatives promoting animal health. The region's advanced veterinary healthcare infrastructure and research capabilities also foster the development and adoption of brucellosis vaccines. Animal husbandry has been a substantial factor in increasing the demand for vaccination in the region. Biological research is encouraging the development of disease-specific vaccinations for animal welfare.

Region with highest CAGR:

The Asia Pacific is estimated to grow at a considerable growth rate in the market during the forecast period. This growth can be accredited to the continuous rise in meat consumption and trade in the region, especially in China. China's increasing demand for meat makes it one of the largest markets for animal healthcare products for livestock animals. Increasing demand for dairy and meat products, coupled with a surge in animal husbandry practices, has fueled the need for effective vaccines.

Key players in the market

Some of the key players in Brucellosis Vaccine market include Biogenesis-Bago, Biovet, Boehringer Ingelheim, Calier, Ceva Sante Animale, Colorado Serum, CZ Veterinaria, Hester Biosciences, Indian Immunologicals, Onderstepoort Biological, Qilu, SYVA Laboratorios, Technovax and Zoetis.

Key Developments:

In January 2024, Ceva Sante Animale, acquired US-based Scout Bio, a biotech company focused on pet therapies. The move represents a significant leap in innovation for Ceva, unlocking access to key advancements including a pipeline of monoclonal antibodies and gene therapy developments to address chronic diseases in pets.

In November 2023, Boehringer Ingelheim and IBM announced an agreement that will enable Boehringer to use IBM's foundation model technologies to discover novel candidate antibodies for the development of efficient therapeutics. Boehringer will be using an IBM-developed, pre-trained AI model that will be further fine-tuned on additional Boehringer proprietary data.

Vaccine Types Covered:

  • DNA Vaccine
  • Subunit Vaccine
  • Inactivated
  • Live Attenuated
  • mRNA Vaccines
  • Vector Vaccine
  • Viral vector vaccines
  • Other Vaccine Types

Diseases Covered:

  • Viral Diseases
  • Bacterial Vaccines
  • Allergy Vaccines
  • Cancer Vaccines
  • Other Diseases

Distribution Channels Covered:

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Other Distribution Channels

Applications Covered:

  • Cattle
  • Goat
  • Horses
  • Sheep
  • Swine
  • Other Applications

End Users Covered:

  • Veterinary Hospitals & Clinics
  • Animal Care Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Brucellosis Vaccine Market, By Vaccine Type

  • 5.1 Introduction
  • 5.2 DNA Vaccine
  • 5.3 Subunit Vaccine
    • 5.3.1 Conjugate Vaccines
    • 5.3.2 Recombinant vaccines
    • 5.3.3 Toxoid vaccines
  • 5.4 Inactivated
  • 5.5 Live Attenuated
  • 5.6 mRNA Vaccines
  • 5.7 Vector Vaccine
  • 5.8 Viral vector vaccines
  • 5.9 Other Vaccine Types

6 Global Brucellosis Vaccine Market, By Disease

  • 6.1 Introduction
  • 6.2 Viral Diseases
    • 6.2.1 Covid-19
    • 6.2.2 Hepatitis
    • 6.2.3 Herpes Zoster
    • 6.2.4 Human Papilloma Virus
    • 6.2.5 Measles, Mumps, and Rubella
    • 6.2.6 Influenza
    • 6.2.7 Rotavirus
    • 6.2.8 Other Viral Diseases
  • 6.3 Bacterial Vaccines
    • 6.3.1 Diphtheria Pertussis Tetanus
    • 6.3.2 Pneumococcal Diseases
    • 6.3.3 Meningococcal Diseases
    • 6.3.4 Other Bacterial Vaccines
  • 6.4 Allergy Vaccines
  • 6.5 Cancer Vaccines
  • 6.6 Other Diseases

7 Global Brucellosis Vaccine Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Hospital & Retail Pharmacies
  • 7.3 Government Suppliers
  • 7.4 Other Distribution Channels

8 Global Brucellosis Vaccine Market, By Application

  • 8.1 Introduction
  • 8.2 Cattle
  • 8.3 Goat
  • 8.4 Horses
  • 8.5 Sheep
  • 8.6 Swine
  • 8.7 Other Applications

9 Global Brucellosis Vaccine Market, By End User

  • 9.1 Introduction
  • 9.2 Veterinary Hospitals & Clinics
  • 9.3 Animal Care Centers
  • 9.4 Other End Users

10 Global Brucellosis Vaccine Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Biogenesis-Bago
  • 12.2 Biovet
  • 12.3 Boehringer Ingelheim
  • 12.4 Calier
  • 12.5 Ceva Sante Animale
  • 12.6 Colorado Serum
  • 12.7 CZ Veterinaria
  • 12.8 Hester Biosciences
  • 12.9 Indian Immunologicals
  • 12.10 Onderstepoort Biological
  • 12.11 Qilu
  • 12.12 SYVA Laboratorios
  • 12.13 Technovax
  • 12.14 Zoetis

List of Tables

  • Table 1 Global Brucellosis Vaccine Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Brucellosis Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
  • Table 3 Global Brucellosis Vaccine Market Outlook, By DNA Vaccine (2021-2030) ($MN)
  • Table 4 Global Brucellosis Vaccine Market Outlook, By Subunit Vaccine (2021-2030) ($MN)
  • Table 5 Global Brucellosis Vaccine Market Outlook, By Conjugate Vaccines (2021-2030) ($MN)
  • Table 6 Global Brucellosis Vaccine Market Outlook, By Recombinant vaccines (2021-2030) ($MN)
  • Table 7 Global Brucellosis Vaccine Market Outlook, By Toxoid vaccines (2021-2030) ($MN)
  • Table 8 Global Brucellosis Vaccine Market Outlook, By Inactivated (2021-2030) ($MN)
  • Table 9 Global Brucellosis Vaccine Market Outlook, By Live Attenuated (2021-2030) ($MN)
  • Table 10 Global Brucellosis Vaccine Market Outlook, By mRNA Vaccines (2021-2030) ($MN)
  • Table 11 Global Brucellosis Vaccine Market Outlook, By Vector Vaccine (2021-2030) ($MN)
  • Table 12 Global Brucellosis Vaccine Market Outlook, By Viral vector vaccines (2021-2030) ($MN)
  • Table 13 Global Brucellosis Vaccine Market Outlook, By Other Vaccine Types (2021-2030) ($MN)
  • Table 14 Global Brucellosis Vaccine Market Outlook, By Disease (2021-2030) ($MN)
  • Table 15 Global Brucellosis Vaccine Market Outlook, By Viral Diseases (2021-2030) ($MN)
  • Table 16 Global Brucellosis Vaccine Market Outlook, By Covid-19 (2021-2030) ($MN)
  • Table 17 Global Brucellosis Vaccine Market Outlook, By Hepatitis (2021-2030) ($MN)
  • Table 18 Global Brucellosis Vaccine Market Outlook, By Herpes Zoster (2021-2030) ($MN)
  • Table 19 Global Brucellosis Vaccine Market Outlook, By Human Papilloma Virus (2021-2030) ($MN)
  • Table 20 Global Brucellosis Vaccine Market Outlook, By Measles, Mumps, and Rubella (2021-2030) ($MN)
  • Table 21 Global Brucellosis Vaccine Market Outlook, By Influenza (2021-2030) ($MN)
  • Table 22 Global Brucellosis Vaccine Market Outlook, By Rotavirus (2021-2030) ($MN)
  • Table 23 Global Brucellosis Vaccine Market Outlook, By Other Viral Diseases (2021-2030) ($MN)
  • Table 24 Global Brucellosis Vaccine Market Outlook, By Bacterial Vaccines (2021-2030) ($MN)
  • Table 25 Global Brucellosis Vaccine Market Outlook, By Diphtheria Pertussis Tetanus (2021-2030) ($MN)
  • Table 26 Global Brucellosis Vaccine Market Outlook, By Pneumococcal Diseases (2021-2030) ($MN)
  • Table 27 Global Brucellosis Vaccine Market Outlook, By Meningococcal Diseases (2021-2030) ($MN)
  • Table 28 Global Brucellosis Vaccine Market Outlook, By Other Bacterial Vaccines (2021-2030) ($MN)
  • Table 29 Global Brucellosis Vaccine Market Outlook, By Allergy Vaccines (2021-2030) ($MN)
  • Table 30 Global Brucellosis Vaccine Market Outlook, By Cancer Vaccines (2021-2030) ($MN)
  • Table 31 Global Brucellosis Vaccine Market Outlook, By Other Diseases (2021-2030) ($MN)
  • Table 32 Global Brucellosis Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 33 Global Brucellosis Vaccine Market Outlook, By Hospital & Retail Pharmacies (2021-2030) ($MN)
  • Table 34 Global Brucellosis Vaccine Market Outlook, By Government Suppliers (2021-2030) ($MN)
  • Table 35 Global Brucellosis Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 36 Global Brucellosis Vaccine Market Outlook, By Application (2021-2030) ($MN)
  • Table 37 Global Brucellosis Vaccine Market Outlook, By Cattle (2021-2030) ($MN)
  • Table 38 Global Brucellosis Vaccine Market Outlook, By Goat (2021-2030) ($MN)
  • Table 39 Global Brucellosis Vaccine Market Outlook, By Horses (2021-2030) ($MN)
  • Table 40 Global Brucellosis Vaccine Market Outlook, By Sheep (2021-2030) ($MN)
  • Table 41 Global Brucellosis Vaccine Market Outlook, By swine (2021-2030) ($MN)
  • Table 42 Global Brucellosis Vaccine Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 43 Global Brucellosis Vaccine Market Outlook, By End User (2021-2030) ($MN)
  • Table 44 Global Brucellosis Vaccine Market Outlook, By Veterinary Hospitals & Clinics (2021-2030) ($MN)
  • Table 45 Global Brucellosis Vaccine Market Outlook, By Animal Care Centers (2021-2030) ($MN)
  • Table 46 Global Brucellosis Vaccine Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.